FindTrial
Sign In

A prospective, single-arm, multi-center real-world study of the clinical effect and safety of Tianshuping (Olmesartan Medoxomil and Amlodipine Besylate Tablets) in patients with essential hypertension

A prospective, single-arm, multi-center real-world study of the clinical effect and safety of Tianshuping (Olmesartan Medoxomil and Amlodipine Besylate Tablets) in patients with essential hypertension

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048938
Enrollment
Unknown
Registered
2021-07-19
Start date
2021-07-19
Completion date
Unknown
Last updated
2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

Experimental group:Tianshuping (Olmesartan Medoxomil and Amlodipine Besylate Tablets)

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with essential hypertension, aged 18-80 years, no gender limit; 2. Patients whose doctors decide to use Tianshuping (olmesartan medoxomil and amlodipine besylate tablets) for antihypertensive treatment according to the drug instructions; 3. Sign the informed consent form and be able to participate in the follow-up on time.

Exclusion criteria

Exclusion criteria: 1. Patients who plan to become pregnant or are pregnant or breastfeeding; 2. Bilateral renal artery stenosis; 3. Hyperkalemia (serum potassium>5.5mmol/L); 4. Chronic renal insufficiency (creatinine>265umol/L).

Design outcomes

Primary

MeasureTime frame
24-hour average systolic blood pressure;—

Countries

China

Contacts

Public ContactChen Xiaoping

West China Hospital, Sichuan University

xiaopingchen15@126.com+86 18980601226

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026